GT Biopharma Inc (GTBP)

[dorijan22]

https://give.umn.edu/stories/clinical-trial-triumph

LOS ANGELES, Feb. 10, 2016 /PRNewswire/ -- Oxis International Inc. (OTC/QB: OXIS) announced today that the company's blood cancer drug, OXS-1550, was described as a "clinical trial triumph" after one of the first patients treated with the drug went into complete cancer remission.

An article on the University of Minnesota's website highlighted one patient whose aggressive and deadly form of cancer went into complete remission after she was treated with OXS-1550. The article described the history of the drug, which was developed by Dr. Daniel Vallera, a research scientist at the University of Minnesota Masonic Cancer Center.

The full text of the article is available here: https://give.umn.edu/stories/clinical-trial-triumph.

Vallera, a scholar and professor in the department of therapeutic radiology, has been studying cancer for more than 30 years. He said the new cancer treatment, which he originally named DT2219, is an injected biologic agent designed to identify cancer cells and kill them, while leaving healthy cells alone.

He has said OXS-1550 is an important alternative to chemotherapy, which kills both cancerous and healthy cells and creates toxicity problems for some patients.

Oxis International holds the worldwide commercial rights for the drug, which it acquired in 2015 and renamed OXS-1550. The Food and Drug Administration has authorized a Phase I/Phase II clinical trial.

One of the first patients to receive the drug was Cynthia Cattell, who said other treatments for her aggressive B-cell lymphoma had failed. Cattell received four infusions of the drug over an eight-day span in the Phase 1 clinical trial.

One month later, a doctor overseeing the clinical trial found a 75 percent reduction in the size of Cattell's tumor, the article said.

Cattell, a University of Minnesota physics professor, received a second round of treatments, which wiped out the tumor. She has been in complete remission for more than 18 months.

After the successful treatment, Cattell was introduced to Dr. Vallera.